Gene Therapy for Malignant Glioma

  • Adam M. Sonabend
  • Ilya V. Ulasov
  • Karen Dana
  • Maciej S. Lesniak
Chapter
First Online:

Abstract

Gliomas are the most common form of primary intracranial malignancy, with glioblastoma multiforme carrying the worst prognosis. Within the context of experimental treatments for this disease, gene and viral oncolytic therapies are two promising and emerging therapeutic strategies. This review explores the different varieties of gene therapy vectors and some of the major advances in the development of oncolytic viruses for targeting these tumors from the preclinical and clinical perspectives. For both gene and oncolytic virotherapy, the limited reach of distant tumor pockets remains a major limitation of their efficacy; thus, some of the initiatives to overcome this obstacle are presented. We attempt a critical review of the available literature with a focus on the present challenges in the field of glioma gene therapy.

Keywords

Brain Tumor Gene Therapy Glioma Cell Herpes Simplex Virus Malignant Glioma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

We would like to thank José Luis Almeida for his kind support with some of the artwork.

References

  1. Adachi Y, Reynolds PN, Yamamoto M et al (2000) Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors. Cancer Res 60: 4305–4310PubMedGoogle Scholar
  2. Andrews DW, Resnicoff M, Flanders AE et al (2001) Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 19: 2189–2200PubMedGoogle Scholar
  3. Anwer K, Kao G, Rolland A et al (2004) Peptide-mediated gene transfer of cationic lipid/plasmid DNA complexes to endothelial cells. J Drug Target 12: 215–221PubMedGoogle Scholar
  4. Asaoka K, Tada M, Sawamura Y et al (2000) Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor. J Neurosurg 92: 1002–1008PubMedGoogle Scholar
  5. Bello L, Lucini V, Giussani C et al (2003) IS20I, a specific alphavbeta3 integrin inhibitor, reduces glioma growth in vivo. Neurosurgery 52: 177–185; discussion 185–186PubMedGoogle Scholar
  6. Bergelson JM, Cunningham JA, Droguett G et al (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320–1323PubMedGoogle Scholar
  7. Bischoff JR, Kirn DH, Williams A et al (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373–376PubMedGoogle Scholar
  8. Boyd M, Mairs RJ, Mairs SC et al (2001) Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill. Oncogene 20: 7804–7808PubMedGoogle Scholar
  9. Braithwaite AW, Russell IA (2001) Induction of cell death by adenoviruses. Apoptosis 6: 359–370PubMedGoogle Scholar
  10. Brown AB, Yang W, Schmidt NO et al (2003) Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum Gene Ther 14: 1777–1785PubMedGoogle Scholar
  11. Chen B, Timiryasova TM, Haghighat P et al (2001) Low-dose vaccinia virus-mediated cytokine gene therapy of glioma. J Immunother 24: 46–57PubMedGoogle Scholar
  12. Chiocca EA, Abbed KM, Tatter S et al (2004) A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10: 958–966PubMedGoogle Scholar
  13. Coffey MC, Strong JE, Forsyth PA et al (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332–1334PubMedGoogle Scholar
  14. Collins VP, James CD (1993) Gene and chromosomal alterations associated with the development of human gliomas. FASEB J 7: 926–930PubMedGoogle Scholar
  15. Colombo F, Barzon L, Franchin E et al (2005) Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther 12: 835–848PubMedGoogle Scholar
  16. Csatary LK, Bakacs T (1999) Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA 281: 1588–1589PubMedGoogle Scholar
  17. Dahlstrand J, Collins VP, Lendahl U (1992) Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 52: 5334–5341Google Scholar
  18. Das A, Tan WL, Teo J et al (2002) Expression of survivin in primary glioblastomas. J Cancer Res Clin Oncol 128: 302–306PubMedGoogle Scholar
  19. Davis ME (2002) Non-viral gene delivery systems. Curr Opin Biotechnol 13: 128–131PubMedGoogle Scholar
  20. DeMasters BK, Markham N, Lillehei KO et al (1997) Differential telomerase expression in human primary intracranial tumors. Am J Clin Pathol 107: 548–554PubMedGoogle Scholar
  21. Dmitriev I, Kashentseva E, Rogers BE et al (2000) Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol 74: 6875–6884PubMedGoogle Scholar
  22. Eck SL, Alavi JB, Judy K et al (2001) Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial. Hum Gene Ther 12: 97–113PubMedGoogle Scholar
  23. Ehtesham M, Kabos P, Kabosova A et al (2002) The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 62: 5657–5663PubMedGoogle Scholar
  24. Ehtesham M, Yuan X, Kabos P et al (2004) Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4. Neoplasia 6: 287–293PubMedGoogle Scholar
  25. Ehtesham M, Stevenson CB, Thompson RC (2005) Stem cell therapies for malignant glioma. Neurosurg Focus 19: E5PubMedGoogle Scholar
  26. Ekstrand AJ, James CD, Cavenee WK et al (1991) Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51: 2164–2172Google Scholar
  27. Felgner PL, Gadek TR, Holm M et al (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84: 7413–7417PubMedGoogle Scholar
  28. Felgner PL, Holm M, Chan H (1989) Cationic liposome mediated transfection. Proc West Pharmacol Soc 32: 115–121PubMedGoogle Scholar
  29. Feng J, Funk WD, Wang SS et al. (1995) The RNA component of human telomerase. Science 269: 1236–1241PubMedGoogle Scholar
  30. Flint J, Shenk T (1997) Viral transactivating proteins. Annu Rev Genet 31: 177–212PubMedGoogle Scholar
  31. Fueyo J, Gomez-Manzano C, Alemany R et al (2000) A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19: 2–12PubMedGoogle Scholar
  32. Fueyo J, Alemany R, Gomez-Manzano C et al (2003) Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95: 652–660PubMedGoogle Scholar
  33. Furnari FB, Huang HJ, Cavenee WK (1995) Genetics and malignant progression of human brain tumours. Cancer Surv 25: 233–275PubMedGoogle Scholar
  34. Geoerger B, Vassal G, Opolon P et al (2004) Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. Cancer Res 64: 5753–5759PubMedGoogle Scholar
  35. Grand RJ, Ibrahim AP, Taylor AM et al (1998) Human cells arrest in S phase in response to adenovirus 12 E1A. Virology 244: 330–342Google Scholar
  36. Graulich W, Nettelbeck DM, Fischer D et al (1999) Cell type specificity of the human endoglin promoter. Gene 227: 55–62PubMedGoogle Scholar
  37. Gridley DS, Andres ML, Li J et al (1998) Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy. Int J Oncol 13: 1093–1098PubMedGoogle Scholar
  38. Grill J, Van Beusechem VW, Van Der Valk P et al (2001) Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin Cancer Res 7: 641–650PubMedGoogle Scholar
  39. Gromeier M, Lachmann S, Rosenfeld MR et al (2000) Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA 97: 6803–6808PubMedGoogle Scholar
  40. Guha A, Dashner K, Black PM et al (1995) Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 60: 168–173PubMedGoogle Scholar
  41. Hamel W, Westphal M, Shepard HM (1993) Loss in expression of the retinoblastoma gene product in human gliomas is associated with advanced disease. J Neurooncol 16: 159–165PubMedGoogle Scholar
  42. Harada K, Kurisu K, Tahara H et al (2000) Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker. J Neurosurg 93: 618–625PubMedGoogle Scholar
  43. Heise C, Sampson-Johannes A, Williams A et al (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3: 639–645PubMedGoogle Scholar
  44. Ichikawa T, Chiocca EA (2001) Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. Cancer Res 61: 5336–5339PubMedGoogle Scholar
  45. Immonen A, Vapalahti M, Tyynela K et al (2004) AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 10: 967–972PubMedGoogle Scholar
  46. Ito H, Aoki H, Kuhnel F et al (2006) Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst 98: 625–636PubMedGoogle Scholar
  47. Jackson CA, Cobbs C, Peduzzi JD et al (2001) Repetitive intrathecal injections of poliovirus replicons result in gene expression in neurons of the central nervous system without pathogenesis. Hum Gene Ther 12: 1827–1841PubMedGoogle Scholar
  48. Jacobs A, Voges J, Reszka R et al (2001) Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358: 727–729PubMedGoogle Scholar
  49. Kajiwara Y, Yamasaki F, Hama S et al (2003) Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97: 1077–1083PubMedGoogle Scholar
  50. Kambara H, Okano H, Chiocca EA et al (2005) An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65: 2832–2839PubMedGoogle Scholar
  51. Kawakami M, Leland P, Kawakami K et al (2001) Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol Res 12: 459–467PubMedGoogle Scholar
  52. Kawakami M, Kawakami K, Takahashi S et al (2004) Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors. Cancer 101: 1036–1042PubMedGoogle Scholar
  53. Khuri FR, Nemunaitis J, Ganly I et al (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879–885PubMedGoogle Scholar
  54. Kim NW, Piatyszek MA, Prowse KR et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011–2015PubMedGoogle Scholar
  55. Kim IA, Yang YJ, Yoon SC et al (2001) Potential of adenoviral p53 gene therapy and irradiation for the treatment of malignant gliomas. Int J Oncol 19: 1041–1047PubMedGoogle Scholar
  56. Klatzmann D, Valery CA, Bensimon G et al (1998) A phase I/II study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 9: 2595–2604PubMedGoogle Scholar
  57. Kleinschmidt-DeMasters BK, Heinz D, McCarthy PJ et al (2003) Survivin in glioblastomas. Protein and messenger RNA expression and comparison with telomerase levels. Arch Pathol Lab Med 127: 826–833PubMedGoogle Scholar
  58. Kohno S, Nakagawa K, Hamada K et al (2004) Midkine promoter-based conditionally replicative adenovirus for malignant glioma therapy. Oncol Rep 12: 73–78PubMedGoogle Scholar
  59. Komata T, Kondo Y, Kanzawa T et al (2001) Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 61: 5796–5802PubMedGoogle Scholar
  60. Kun LE, Gajjar A, Muhlbauer M et al (1995) Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther 6: 1231–1255PubMedGoogle Scholar
  61. Kunwar S (2003) Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 88: 105–111PubMedGoogle Scholar
  62. Lamfers ML, Grill J, Dirven CM et al (2002) Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 62: 5736–5742PubMedGoogle Scholar
  63. Lang FF, Bruner JM, Fuller GN et al (2003) Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21: 2508–2518PubMedGoogle Scholar
  64. Langford LA, Piatyszek MA, Xu R et al (1995) Telomerase activity in human brain tumours. Lancet 346: 1267–1268PubMedGoogle Scholar
  65. Le S, Zhu JJ, Anthony DC et al (1998) Telomerase activity in human gliomas. Neurosurgery 42: 1120–1124; discussion 1124–1125PubMedGoogle Scholar
  66. Lesniak MS (2006) Targeted therapy for malignant glioma: neural stem cells. Expert Rev Neurother 6: 1–3PubMedGoogle Scholar
  67. Lesniak MS, Brem H (2004) Targeted therapy for brain tumours. Nat Rev Drug Discov 3: 499–508PubMedGoogle Scholar
  68. Lesniak MS, Langer R, Brem H (2001) Drug delivery to tumors of the central nervous system. Curr Neurol Neurosci Rep 1: 210–216PubMedGoogle Scholar
  69. Liau LM, Black KL, Prins RM et al (1999) Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90: 1115–1124PubMedGoogle Scholar
  70. Lichtenstein DL, Wold WS (2004) Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther 11: 819–829PubMedGoogle Scholar
  71. Lin E, Nemunaitis J (2004) Oncolytic viral therapies. Cancer Gene Ther 11: 643–664PubMedGoogle Scholar
  72. Ly A, Duc HT, Kalamarides M et al (2001) Human glioma cells transformed by IGF-I triple helix technology show immune and apoptotic characteristics determining cell selection for gene therapy of glioblastoma. Mol Pathol 54: 230–239PubMedGoogle Scholar
  73. Lyons RM, Forry-Schaudies S, Otto E et al (1995) An improved retroviral vector encoding the herpes simplex virus thymidine kinase gene increases antitumor efficacy in vivo. Cancer Gene Ther 2: 273–280PubMedGoogle Scholar
  74. Markert JM, Medlock MD, Rabkin SD et al (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867–874PubMedGoogle Scholar
  75. Matsuno A, Nagashima T (2004) Specific gene suppression using antisense strategy for growth suppression of glioma. Med Electron Microsc 37: 158–161PubMedGoogle Scholar
  76. McConnell MJ, Imperiale MJ (2004) Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 15: 1022–1033PubMedGoogle Scholar
  77. Meyerson M (1998) Telomerase enzyme activation and human cell immortalization. Toxicol Lett 102–103: 41–45PubMedGoogle Scholar
  78. Miller CR, Buchsbaum DJ, Reynolds PN et al (1998) Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 58: 5738–5748PubMedGoogle Scholar
  79. Mintz A, Gibo DM, Slagle-Webb B et al (2002) IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia 4: 388–399PubMedGoogle Scholar
  80. Mischel PS, Shai R, Shi T et al (2003) Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22: 2361–2373PubMedGoogle Scholar
  81. Miyauchi M, Shimada H, Kadomatsu K et al (1999) Frequent expression of midkine gene in esophageal cancer suggests a potential usage of its promoter for suicide gene therapy. Jpn J Cancer Res 90: 469–475PubMedGoogle Scholar
  82. Mizuno M, Yoshida J, Colosi P et al (1998) Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration. Jpn J Cancer Res 89: 76–80PubMedGoogle Scholar
  83. Nakamizo A, Marini F, Amano T et al (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65: 3307–3318PubMedGoogle Scholar
  84. Nakamura K, Ito Y, Kawano Y et al (2004) Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11: 1155–1164PubMedGoogle Scholar
  85. Nandi S, Ulasov IV, Tyler MA et al (2008) Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res 68: 5778–5784PubMedGoogle Scholar
  86. Okada H, Pollack IF, Lotze MT et al (2000) Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther 11: 637–653PubMedGoogle Scholar
  87. Okada H, Pollack IF, Lieberman F et al (2001) Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum Gene Ther 12: 575–595PubMedGoogle Scholar
  88. Oldfield EH, Ram Z, Culver KW et al (1993) Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 4: 39–69PubMedGoogle Scholar
  89. Palu G, Cavaggioni A, Calvi P et al (1999) Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther 6: 330–337PubMedGoogle Scholar
  90. Papanastassiou V, Rampling R, Fraser M et al (2002) The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 9: 398–406PubMedGoogle Scholar
  91. Parr MJ, Manome Y, Tanaka T et al (1997) Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 3: 1145–1149PubMedGoogle Scholar
  92. Phuong LK, Allen C, Peng KW et al (2003) Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 63: 2462–2469PubMedGoogle Scholar
  93. Prados MD, McDermott M, Chang SM et al (2003) Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial. J Neurooncol 65: 269–278PubMedGoogle Scholar
  94. Pulkkanen KJ, Yla-Herttuala S (2005) Gene therapy for malignant glioma: current clinical status. Mol Ther 12: 585–598PubMedGoogle Scholar
  95. Raffel C, Culver K, Kohn D, et al (1994) Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther 5: 863–890PubMedGoogle Scholar
  96. Rainov NG (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11: 2389–2401PubMedGoogle Scholar
  97. Rainov NG, Ren H (2003) Clinical trials with retrovirus mediated gene therapy–what have we learned? J Neurooncol 65: 227–236PubMedGoogle Scholar
  98. Ramachandra M, Rahman A, Zou A et al (2001) Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol 19: 1035–1041PubMedGoogle Scholar
  99. Rampling R, Cruickshank G, Papanastassiou V et al (2000) Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7: 859–866PubMedGoogle Scholar
  100. Ren H, Boulikas T, Lundstrom K et al (2003) Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene--a phase I/II clinical protocol. J Neurooncol 64: 147–154PubMedGoogle Scholar
  101. Russell SJ (2002) RNA viruses as virotherapy agents. Cancer Gene Ther 9: 961–966PubMedGoogle Scholar
  102. Saikali S, Avril T, Collet B et al (2007) Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol 81: 139–148PubMedGoogle Scholar
  103. Sakiyama S, Yu L, Tomizawa M et al (2003) Utilization of the promoter region of the midkine gene as a tool to drive therapeutic genes in a tumor specific manner. Adv Enzyme Regul 43: 57–66PubMedGoogle Scholar
  104. Sandmair AM, Loimas S, Puranen P et al (2000) Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 11: 2197–2205PubMedGoogle Scholar
  105. Schatzlein AG (2001) Non-viral vectors in cancer gene therapy: principles and progress. Anticancer Drugs 12: 275–304PubMedGoogle Scholar
  106. Serfozo P, Schlarman MS, Pierret C et al (2006) Selective migration of neuralized embryonic stem cells to stem cell factor and media conditioned by glioma cell lines. Cancer Cell Int 6: 1PubMedGoogle Scholar
  107. Shah AC, Benos D, Gillespie GY et al (2003) Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol 65: 203–226PubMedGoogle Scholar
  108. Shai R, Shi T, Kremen TJ et al (2003) Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22: 4918–4923PubMedGoogle Scholar
  109. Shi N, Pardridge WM (2000) Noninvasive gene targeting to the brain. Proc Natl Acad Sci USA 97: 7567–7572PubMedGoogle Scholar
  110. Shimato S, Natsume A, Takeuchi H et al (2007) Human neural stem cells target and deliver therapeutic gene to experimental leptomeningeal medulloblastoma. Gene Ther 14: 1132–1142PubMedGoogle Scholar
  111. Shinoura N, Saito K, Yoshida Y et al (2000) Adenovirus-mediated transfer of bax with caspase-8 controlled by myelin basic protein promoter exerts an enhanced cytotoxic effect in gliomas. Cancer Gene Ther 7: 739–748PubMedGoogle Scholar
  112. Sonabend AM, Ulasov IV, Han Y et al (2006) Oncolytic adenoviral therapy for glioblastoma multiforme. Neurosurg Focus 20: E19PubMedGoogle Scholar
  113. Sonabend AM, Ulasov IV, Lesniak MS (2007) Gene therapy trials for the treatment of high-grade gliomas. Gene Ther Mol Biol 11: 79–92PubMedGoogle Scholar
  114. Sonabend AM, Ulasov IV, Dana K, Lesniak MS. Gene and Viral Oncolytic Therapies for Malignant Glioma. New Gene Therapy and Cancer Research. Nova Science Publishers. New York 2008.Google Scholar
  115. Sonabend AM, Ulasov IV, Tyler MA et al (2008a) Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 26: 831–841PubMedGoogle Scholar
  116. Sonabend AM, Velicu S, Ulasov IV et al (2008b) A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma. Anticancer Drugs 19: 133–142PubMedGoogle Scholar
  117. Srinivasula SM, Ahmad M, MacFarlane M et al (1998) Generation of constitutively active recombinant caspases-3 and -6 by rearrangement of their subunits. J Biol Chem 273: 10107–10111PubMedGoogle Scholar
  118. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987–996PubMedGoogle Scholar
  119. Suzuki K, Fueyo J, Krasnykh V et al (2001) A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 7: 120–126PubMedGoogle Scholar
  120. Timiryasova TM, Chen B, Haghighat P et al (1999) Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis. Int J Oncol 14: 845–854PubMedGoogle Scholar
  121. Tollefson AE, Scaria A, Hermiston TW et al (1996) The adenovirus death protein (E3–11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 70: 2296–2306PubMedGoogle Scholar
  122. Tomizawa M, Yu L, Wada A et al (2003) A promoter region of the midkine gene that is frequently expressed in human hepatocellular carcinoma can activate a suicide gene as effectively as the alpha-fetoprotein promoter. Br J Cancer 89: 1086–1090PubMedGoogle Scholar
  123. Tomko RP, Xu R, Philipson L (1997) HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94: 3352–3356PubMedGoogle Scholar
  124. Tyler M, Ulasov I, Sonabend A et al (2009) Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Therapy 16: 262–278PubMedGoogle Scholar
  125. Ueki K, Ono Y, Henson JW et al (1996) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56: 150–153PubMedGoogle Scholar
  126. Uhm JH, Gladson CL, Rao JS (1999) The role of integrins in the malignant phenotype of gliomas. Front Biosci 4: D188–D199PubMedGoogle Scholar
  127. Ulasov IV, Rivera AA, Sonabend AM et al (2007a) Comparative evaluation of Survivin, Midkine, and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol Ther 6: 679–685PubMedGoogle Scholar
  128. Ulasov IV, Tyler MA, Han Y et al (2007b) Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma. Hum Gene Ther 18: 118–129PubMedGoogle Scholar
  129. Ulasov IV, Zhu ZB, Tyler MA et al (2007c) Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 18: 589–602PubMedGoogle Scholar
  130. van Beusechem VW, Grill J, Mastenbroek DC et al (2002) Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J Virol 76: 2753–2762PubMedGoogle Scholar
  131. Vandier D, Rixe O, Besnard F et al (2000) Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. Cancer Gene Ther 7: 1120–1126PubMedGoogle Scholar
  132. Vile RG, Russell SJ (1995) Retroviruses as vectors. Br Med Bull 51: 12–30PubMedGoogle Scholar
  133. Voges J, Reszka R, Gossmann A et al (2003) Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 54: 479–487PubMedGoogle Scholar
  134. Wong AJ, Bigner SH, Bigner DD et al (1987) Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84: 6899–6903PubMedGoogle Scholar
  135. Yang L, Cao Z, Li F et al (2004a) Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther 11: 1215–1223PubMedGoogle Scholar
  136. Yang WQ, Lun X, Palmer CA et al (2004b) Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res 10: 8561–8576PubMedGoogle Scholar
  137. Yoshida J, Mizuno M, Fujii M et al (2004a) Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. Hum Gene Ther 15: 77–86PubMedGoogle Scholar
  138. Yoshida J, Mizuno M, Wakabayashi T (2004b) Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci 95: 858–865PubMedGoogle Scholar
  139. Yu JS, Wheeler CJ, Zeltzer PM et al (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61: 842–847PubMedGoogle Scholar
  140. Yu L, Ugai S, J OW et al (2003) Cell growth- and P53-dependent transcriptional activity of the midkine promoter confers suicide gene expression in tumor cells. Oncol Rep 10: 1301PubMedGoogle Scholar
  141. Yu JS, Liu G, Ying H et al (2004a) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64: 4973–4979PubMedGoogle Scholar
  142. Yu L, Hamada K, Namba M et al (2004b) Midkine promoter-driven suicide gene expression and -mediated adenovirus replication produced cytotoxic effects to immortalised and tumour cells. Eur J Cancer 40: 1787–1794PubMedGoogle Scholar
  143. Yu L, Yamamoto N, Kadomatsu K et al (2004c) Midkine promoter can mediate transcriptional activation of a fused suicide gene in a broader range of human breast cancer compared with c-erbB-2 promoter. Oncology 66: 143–149PubMedGoogle Scholar
  144. Zhang Y, Cui J, Liu X et al (1998) MR imaging in rat glioma model and gene therapy using EGFR antisence RNA. Chin Med J (Engl) 111: 993–997Google Scholar
  145. Zhang J, Frolov I, Russell SJ (2004) Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein. J Gene Med 6: 1082–1091PubMedGoogle Scholar
  146. Zheng S, Ulasov IV, Han Y et al (2007) Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med 9: 151–160PubMedGoogle Scholar
  147. Ziu M, Schmidt NO, Cargioli TG et al (2006) Glioma-produced extracellular matrix influences brain tumor tropism of human neural stem cells. J Neurooncol 79: 125–133PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Adam M. Sonabend
  • Ilya V. Ulasov
  • Karen Dana
  • Maciej S. Lesniak
    • 1
  1. 1.Section of NeurosurgeryThe University of Chicago Pritzker School of MedicineMC 3026 ChicagoUSA

Personalised recommendations